Diagnosis of congenital CMV infection via DBS samples testing and neonatal hearing screening: an observational study in Italy.

A new interesting article has been published in BMC Infect Dis. 2019 Jul 22;19(1):652. doi: 10.1186/s12879-019-4296-5. and titled:

Diagnosis of congenital CMV infection via DBS samples testing and neonatal hearing screening: an observational study in Italy.

Authors of this article are:

Pellegrinelli L, Galli C, Primache V, Alde’ M, Fagnani E, Di Berardino F, Zanetti D, Pariani E, Ambrosetti U, Binda S.

A summary of the article is shown below:

BACKGROUND: Congenital Cytomegalovirus (cCMV) is the most common cause of non-genetic hearing loss in childhood. A newborn hearing screening program (NHSP) is currently running in Italy, but no universal cCMV nor statewide hearing-targeted CMV screening programs have been implemented yet. This observational monocentric study was aimed at estimating the rate of cCMV infections identified by CMV-DNA analysis on Dried Blood Spots (DBS) samples in deaf children identified via NHSP in Northern Italy in the period spanning from 2014 to 2018.METHODS: Children with a confirmed diagnosis of deafness and investigated for CMV-DNA by nucleic acid extraction and in-house polymerase-chain reaction (PCR) on stored newborns screening cards (DBS-test) were included in this study. Deafness was defined by a hearing threshold ≥20 decibel (dB HL) by Auditory Brainstem Responses (ABR); all investigated DBS samples were collected within 3 days of life.RESULTS: Overall, 82 children were included (median age: 3.4 months; lower-upper quartiles: 2-5.3 months; males: 60.9%). Most of them (70.7%) presented bilateral hearing loss with a symmetrical pattern in 79.3% of the cases. ABR thresholds were ≥ 70 dB HL (severe/profound deafness) in 46.5% of children. Among all tested children, 6.1% resulted positive for cCMV. The rate of severe/profound deafness was statistically higher in children with cCMV infection.CONCLUSIONS: The addition of DBS-test to the NHSP allowed the identification, in their first months of life, of a cCMV infection in 6.1% of children who had failed NHS. The introduction of a targeted CMV screening strategy could help clinicians in the differential diagnosis and in the babies’ management. DBS samples can be considered a “universal newborns biobank”: their storage site and duration should be the subject of political decision-making.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as: Congenital Cytomegalovirus;Dried blood spot;Hearing loss;Neonatal hearing screening program.

New Chemicals from MOLECULAR DEPOT

New Proteins from MOLECULAR DEPOT

New Antibodies from MOLECULAR DEPOT

New Research Kits from MOLECULAR DEPOT

Molecular Depot

Your specialty peptide, proteins, antibodies and chemical compounds store.